Please login to the form below

Not currently logged in
Email:
Password:

Astellas and Regeneron extend deal

Astellas has agreed to pay Regeneron $295m to extend its non-exclusive licence of the company's VelocImmune drug-discovery technology to 2023

Astellas has agreed to pay Regeneron $295m to extend its non-exclusive licence of the company's VelocImmune drug-discovery technology through the year 2023.

The licence allows Astellas to make use of VelocImmune technology in its internal research programs to discover fully human monoclonal antibody product candidates. The deal calls for a $165m upfront payment, with another $130m due in June 2018. Astellas will also pay a mid-single-digit royalty on product sales of any marketed therapies developed using the technology.

The companies forged their original six-year licensing deal in early 2007. That deal, which is overturned by the new agreement, called for Astellas to make licensing payments of $20m per year during 2007 to 2010.

Although no Astellas products making use of the technology have yet been approved, about 20 monoclonal antibody projects using VelocImmune are ongoing at the company. Astellas said that the extension of the deal is part of its recently announced mid-term management plan toward the financial year 2014, which calls for the company to put "the highest strategic priority on the development of antibody drugs."

The VelocImmune technology generates fully human monoclonal antibodies (hMAbs) to address clinically relevant targets.

28th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics